Eyenovia advances microline for the treatment of presbyopia towards phase iii development and reprioritizes late-stage ophthalmology pipeline

Eyenovia advances microline for the treatment of presbyopia towards phase iii development and reprioritizes late-stage ophthalmology pipeline.eyenovia inc - defers development activities of microprost and microtears.eyenovia inc - anticipate initiating and completing phase iii vision trials for microline in 2020.eyenovia inc - expects reprioritization of its programs to yield overall cost savings to eyenovia of approximately $1.5 to $1.9 million in 2020..
EYEN Ratings Summary
EYEN Quant Ranking